STOCKS TELEGRAPH

Tag: FBIO STOCK

  • What Is Propelling Fortress Biotech (FBIO) Stock Today?

    What Is Propelling Fortress Biotech (FBIO) Stock Today?

    Fortress Biotech, Inc. (NASDAQ: FBIO) is experiencing a notable upswing on the US stock charts today. The stock of Fortress Biotech has appreciated by 4.55% as of the last check in the current trading session, reaching a value of $3.45. This surge in FBIO stock value is attributed to a recent strategic maneuver undertaken by its subsidiary.

    This week, Fortress Biotech (FBIO) formally disclosed that its wholly-owned entity, Cyprium Therapeutics, has executed an Assignment and Assumption Agreement. This agreement has been formalized with Sentynl Therapeutics, a specialized pharmaceutical company based in the United States and wholly owned by Zydus Lifesciences Ltd.

    Within the framework of this agreement, the FBIO subsidiary successfully transferred its proprietary rights and assigned its FDA-related documentation for CUTX-101, a Copper Histidinate product candidate designed for the treatment of Menkes disease, to Sentynl.

    At the closing of the deal, Cyprium received a sum of $4.5 million and retains the potential to earn up to $129 million in combined development and sales milestones as specified in the Agreement. Furthermore, the FBIO subsidiary stands to receive royalties based on the net sales of CUTX-101.

    FBIO will receive 3% of revenue from net sales up to $75 million, increasing to 8.75% if sales exceed $75 million. If sales exceed $100 million, then FBIO subsidiaries will receive 12.5% of revenue. With progress underway in the CUTX-101 rolling NDA submission, Cyprium anticipates that Sentynl will conclude the filing process in 2024.

    The transition of the CUTX-101 program to Sentynl is expected to result in a reduction in Cyprium’s development-related expenditures while potentially expediting the commercialization process post-FDA approval.

    The drug has exhibited a compelling safety and efficacy profile for Menkes disease treatment. If approved, CUTX-101 stands to address a significant unmet need for children afflicted by this rare and fatal pediatric condition. Cyprium will maintain full ownership of any FDA priority review voucher issued upon NDA approval for CUTX-101.

  • Fortess Biotech Inc. (FBIO) soared in the after-market trading session; here’s why

    Fortess Biotech Inc. (FBIO) soared in the after-market trading session; here’s why

    Fortress Biotech Inc. (FBIO) stock was rising by 8.82% to trade at the price of %5.92 in the aftermarket, at the time of writing. FBIO’s stock closed in Friday’s session by trading at $5.44 which is an 11.48% gain. The stock volume traded is 22 million shares which is higher than the average daily volume of 1.63 million for the past 50 days. FBIO shares had moved by 41.30% in the past week and in the past three months It gained 56.77%. Furthermore, for the past 6 months and 12 months, it has added 26.22% and 186.32% respectively.

    Fortress’s operational activities in April

    Fortress Biotech Inc. and specifically its partner Journey Medical Corporation’s stock have been performing fundamentally well recently and they have been very active operation activity-wise in the start of April.

    Fortress BioTech Inc. (NASDAQ: FBIO) announced on 7th April 2021 that it will participate on the 20th Annual Needham Virtual Healthcare Conference which will take place from today 12th to 15th of April. Fortress’s Chief Executive Officer, President, and Chairman, LindsayA. Rosenwald, M.D, will participate in the meeting as well as one-on-one meetings during the conference. The company’s presentation will be available on their website link (click here)

    On 5th April, the partner company of Fortress BiotTech, Inc. named Journey Medical Corporation announced that it has entered into an agreement on Line of Credit with East West Bank for the amount of $7.5 million. This line of credit will be entered and received into receivables and cash of the company with an interest rate greater of 4.25%.

    On 1sth April, the Journey Medical Corporation had announced an agreement to acquire Qbrexza (glycopyrronium) which is the treatment of primary axillary hypherhidrosis in adults and pediatric populations, as well as self-administered patients. This issue is pertinent to the characterization of excessive sweating on the hand’s palms, soles of feet, armpit, groin area and under the breasts. Qbrexza is approved by the Food and Drug Administration and has generated $24 million net sales in the USA, 2020. Journey Medical Corporation will close the transaction early in the second quarter of this year.

    Fortress Biotech Inc.’s candidate programs and acquisitions

    Fortress Biotech Inc. is a biopharmaceutical company that focuses mainly on acquisition, development and commercialization of high-potential marketed and development-stage drugs and drug candidates. The product candidates that Fortress currently has in its pipeline include the bio-pharmaceutical areas of oncology, gene therapy and rare diseases. For these areas of expertise, 7 of the candidates have been marketed as pharmaceutically prescribed products and over 25 programs in development progress. Together these developed and developing products in the pipeline cover 6 large market areas which show that the FBIO stock is highly diversified.

    The business model

    To maintain these diversified and expansionary operational activities, FBIO has a team model structured around world-class business development team that has the expertise of the biopharmaceutical industry. This is highly crucial for the company to expand the company into new avenues of biopharmaceutical product opportunities.

    FBIO stock, as an opportunity to expand biopharmaceutical products, has extended partnerships with several world-renowned and famous biopharmaceutical companies as well as institutions which include AstraZeneca, Fred Hutchinson Cancer Research Center, Nationwide Children’s Hospital as well as many others.